CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7170 result(s)

Workshop: Combining Different Types of Evidence on Effectiveness, Implementation, and Views to Better Understand Complex Interventions

Event Date: April 14, 2021
Result type: Events

Audience: Producers
Level: Intermediate What you’ll learn: Workshop participants will: 1) articulate the differences between traditional effectiveness reviews and mixed methods research syntheses (MMRS); 2) identify when an MMRS would be appropriate; 3) demonstrate an understanding of the different stages of MMRS. Dr. Quan Nha Hong, In...

Workshop – Diagnostic Test Accuracy Meta-Analysis

Event Date: March 10, 2021
Result type: Events

Audience: Of interest to HTA producers. Level: Intermediate  What you’ll learn: Knowledge of methods needed to carry out a meta-analysis of diagnostic test accuracy, including the methods needed to correct for imperfect reference standard. Dr. Nandini Dendukuri, McGill University Ian Schiller, McGill University Health Centre‒Research ...

CADTH COVID-19 Webinar - Women's Issues in Pandemic Times: How COVID-19 Has Exacerbated Gender Inequities for Women in Canada and Around the World

Event Date: March 8, 2021
Result type: Events

International Women’s Day is a worldwide event that connects men and women in celebration of the social, economic, cultural, and political achievements of women. In honour of this day, CADTH is hosting this special webinar.  Despite progress in women's issues in recent decades, there is concern that the COVID-19 pandemic has accentuated ex...

Workshop - Supporting Decision-Making in an Uncertain Future: A Hands-On Introduction to Horizon Scanning in Health Technology Management

Event Date: March 3, 2021
Result type: Events

Audience: Of interest to HTA producers. Level: Introductory What you’ll learn: By the end of this workshop, you will understand the role horizon scanning plays in health technology management (HTM), know about sources and processes to identify and prioritize horizon scanning topics, and be able to apply processes to real-world examples. Jef...

risperidone (Perseris )

Last Updated: March 1, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: risperidone
Indications: ​Treatment of schizophrenia in adults.

  • Brand Name: Perseris
  • Manufacturer: HLS Therapeutics Inc.
  • Project Number: SR0671-000
  • Project Status: Active
  • Submission Type: Initial

incobotulinumtoxin A (Xeomin)

Last Updated: March 1, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: incobotulinumtoxin A
Indications: ​For the treatment of chronic sialorrhea associated with neurological disorders in adults.

  • Brand Name: Xeomin
  • Manufacturer: Merz Pharmaceuticals GMBH
  • Project Number: SR0678-000
  • Project Status: Received
  • Submission Type: Initial

larotrectinib (Vitrakvi)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: larotrectinib
Indications: For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.

  • Brand Name: Vitrakvi
  • Manufacturer: Bayer Inc.
  • Project Number: PC0221-000
  • Project Status: Active
  • Submission Type: Resubmission

patiromer (Veltassa)

Last Updated: December 21, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: patiromer
Indications: For the treatment of hyperkalemia in adults with chronic kidney disease (eGFR ≥15mL/min/1.73m).

  • Brand Name: Veltassa
  • Manufacturer: Otsuka Canada Pharmaceuticals Inc.
  • Project Number: SR0665-000
  • Project Status: Active
  • Submission Type: Initial

nintedanib (Ofev)

Last Updated: February 26, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: nintedanib
Indications: Treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as progressive fibrosing ILD)

  • Brand Name: Ofev
  • Manufacturer: Boehringer Ingelheim (Canada) Ltd.
  • Project Number: SR0654-000
  • Project Status: Active
  • Submission Type: Initial